Last reviewed · How we verify
Dose expansion: The maximum tolerated dose of CAR-T cells
Dose expansion: The maximum tolerated dose of CAR-T cells is a Biologic drug developed by Medical College of Wisconsin. It is currently in Phase 1 development.
At a glance
| Generic name | Dose expansion: The maximum tolerated dose of CAR-T cells |
|---|---|
| Sponsor | Medical College of Wisconsin |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Lymphocyte count decreased
- Neutrophil count decreased
- White blood cell decreased
- Hypertension
- Hypokalemia
- Platelet count decreased
- Somnolence
- Anorexia
- Aspartate aminotransferase increased
- Bone pain
- Fatigue
Key clinical trials
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (PHASE1)
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (PHASE1)
- TriPRIL CAR T Cells in Multiple Myeloma (PHASE1)
- Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma (PHASE1)
- Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (PHASE1)
- Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer (EARLY_PHASE1)
- B7-H3.CD28Z.CART in CNS Neoplasms (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose expansion: The maximum tolerated dose of CAR-T cells CI brief — competitive landscape report
- Dose expansion: The maximum tolerated dose of CAR-T cells updates RSS · CI watch RSS
- Medical College of Wisconsin portfolio CI
Frequently asked questions about Dose expansion: The maximum tolerated dose of CAR-T cells
What is Dose expansion: The maximum tolerated dose of CAR-T cells?
Dose expansion: The maximum tolerated dose of CAR-T cells is a Biologic drug developed by Medical College of Wisconsin.
Who makes Dose expansion: The maximum tolerated dose of CAR-T cells?
Dose expansion: The maximum tolerated dose of CAR-T cells is developed by Medical College of Wisconsin (see full Medical College of Wisconsin pipeline at /company/medical-college-of-wisconsin).
What development phase is Dose expansion: The maximum tolerated dose of CAR-T cells in?
Dose expansion: The maximum tolerated dose of CAR-T cells is in Phase 1.
What are the side effects of Dose expansion: The maximum tolerated dose of CAR-T cells?
Common side effects of Dose expansion: The maximum tolerated dose of CAR-T cells include Anemia, Lymphocyte count decreased, Neutrophil count decreased, White blood cell decreased, Hypertension, Hypokalemia.
Related
- Manufacturer: Medical College of Wisconsin — full pipeline